Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/17405

TDMS Study 99035-01 Pathology Tables

NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04
Route: GAVAGE                                                                                                     Time: 12:54:57

                                                            FINAL #1




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  556-52-5

       Lock Date:  09/24/01

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) FEMALE         0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15                        
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 2            1            2            1            4                        
    Natural Death                                                                1                         2                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                13           14           12           14            9                        
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15                        
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Colon                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                                     1 (7%)                                
   Intestine Large, Rectum                            (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                                                  1 (7%)                   
   Intestine Small, Duodenum                          (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                        4 (27%)      1 (7%)       1 (7%)                   
   Intestine Small, Jejunum                           (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           3 (20%)      3 (20%)      1 (7%)                                
   Intestine Small, Ileum                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           2 (13%)      2 (13%)      1 (7%)       1 (7%)                   
   Liver                                              (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              5 (33%)      1 (7%)       8 (53%)      5 (33%)      8 (53%)                  
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                      1 (7%)                                                          
   Mesentery                                                                    (2)                                                 
      Histiocytic Sarcoma                                                        2 (100%)                                           
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)                    1 (7%)                                
      Squamous Cell Papilloma                                                                 1 (7%)       3 (20%)                  
   Stomach, Glandular                                 (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)       1 (7%)       2 (13%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)       2 (13%)      2 (13%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) FEMALE         0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              3 (20%)                   7 (47%)      2 (13%)      1 (7%)                   
   Adrenal Medulla                                    (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)                                                                       
   Pituitary Gland                                    (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)                    2 (13%)      1 (7%)       1 (7%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              8 (53%)      5 (33%)      8 (53%)      6 (40%)      5 (33%)                  
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                      1 (7%)                                                          
   Uterus                                             (15)         (15)         (15)         (15)         (15)                      
      Hemangiosarcoma, Metastatic, Spleen                                        1 (7%)                                             
      Histiocytic Sarcoma                                                        4 (27%)      4 (27%)      5 (33%)                  
      Sarcoma Stromal                                                                                      1 (7%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (15)         (15)         (15)         (15)         (15)                      
      Hemangiosarcoma                                                                         1 (7%)                                
      Histiocytic Sarcoma                              9 (60%)      8 (53%)     11 (73%)      8 (53%)      8 (53%)                  
   Lymph Node                                         (13)         (15)         (15)         (13)         (14)                      
      Lumbar, Histiocytic Sarcoma                                   2 (13%)      1 (7%)                    2 (14%)                  
      Mediastinal, Histiocytic Sarcoma                 1 (8%)       1 (7%)       6 (40%)      3 (23%)      3 (21%)                  
      Pancreatic, Histiocytic Sarcoma                                            1 (7%)                                             
      Renal, Histiocytic Sarcoma                                    2 (13%)                                1 (7%)                   
   Lymph Node, Mandibular                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)       1 (7%)       6 (40%)      2 (13%)      3 (20%)                  
   Lymph Node, Mesenteric                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              3 (20%)      3 (20%)      5 (33%)      3 (20%)      5 (33%)                  
   Spleen                                             (15)         (15)         (15)         (15)         (15)                      
      Hemangiosarcoma                                                            1 (7%)                                             
      Histiocytic Sarcoma                              2 (13%)      2 (13%)      7 (47%)      3 (20%)      2 (13%)                  
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) FEMALE         0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - cont                                                                                                         
   Thymus                                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)       1 (7%)       6 (40%)      2 (13%)      2 (13%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)                      
      Subcutaneous Tissue, Hemangiosarcoma             1 (7%)                                                                       
      Subcutaneous Tissue, Histiocytic Sarcoma                                   2 (13%)                   1 (7%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                                                                        (2)                       
      Histiocytic Sarcoma                                                                                  2 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (15)         (15)         (15)         (15)         (15)                      
      Choristoma                                                                                           1 (7%)                   
      Histiocytic Sarcoma                              1 (7%)                    4 (27%)      4 (27%)      2 (13%)                  
   Spinal Cord                                                                                            (1)                       
      Histiocytic Sarcoma                                                                                  1 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)                      
      Alveolar/Bronchiolar Adenoma                                  1 (7%)                    1 (7%)       4 (27%)                  
      Alveolar/Bronchiolar Carcinoma                                                          1 (7%)                                
      Histiocytic Sarcoma                              2 (13%)                   6 (40%)      3 (20%)      6 (40%)                  
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                      1 (7%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Zymbal's Gland                                                                            (1)          (1)                       
      Squamous Cell Carcinoma                                                                              1 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) FEMALE         0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)                    4 (27%)      2 (13%)      3 (20%)                  
   Urinary Bladder                                    (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                        2 (13%)      2 (13%)      2 (13%)                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)                      
      Histiocytic Sarcoma                              9 (60%)      9 (60%)     12 (80%)     10 (67%)     13 (87%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) FEMALE         0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            10           9          12          12          14                           
     Total Primary Neoplasms                           10          10          13          14          23                           
                                                                                                                                    
   Total Animals with Benign Neoplasms                              1                       2           7                           
     Total Benign Neoplasms                                         1                       2           7                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms              10           9          12          11          14                           
     Total Malignant Neoplasms                         10           9          13          12          15                           
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                          1           1                                                   
     Total Metastatic Neoplasm                                      3           1                                                   
                                                                                                                                    
   Total Animals with Malignant Neoplasms                           1                                                               
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                  1                           
     Total Uncertain Neoplasms                                                                          1                           
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) MALE           0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15                        
  Early Deaths                                                                                                                      
    Natural Death                                      2            1            1            1            3                        
    Moribund Sacrifice                                                           1                         4                        
    Dosing Accident                                                                                        1                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                13           14           13           14            7                        
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15                        
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Rectum                            (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                        1 (7%)                    1 (7%)                   
   Intestine Large, Cecum                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                        1 (7%)                                             
   Intestine Small, Duodenum                          (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                        1 (7%)                    2 (13%)                  
   Intestine Small, Jejunum                           (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                        2 (13%)      1 (7%)                                
   Intestine Small, Ileum                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                                                  1 (7%)                   
   Liver                                              (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              2 (13%)      2 (13%)      4 (27%)      2 (13%)     10 (67%)                  
   Pancreas                                                                                               (1)                       
      Histiocytic Sarcoma                                                                                  1 (100%)                 
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)                      
      Squamous Cell Papilloma, Multiple                                                                    1 (7%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)                                 5 (33%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) MALE           0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (15)         (15)         (15)         (14)         (15)                      
      Histiocytic Sarcoma                                                                     1 (7%)       1 (7%)                   
   Pituitary Gland                                    (15)         (15)         (14)         (15)         (15)                      
      Histiocytic Sarcoma                                                                                  1 (7%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Epididymis                                         (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                                                     2 (13%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              2 (13%)      5 (33%)      6 (40%)      4 (27%)      8 (53%)                  
   Lymph Node                                         (14)         (14)         (15)         (13)         (13)                      
      Mediastinal, Histiocytic Sarcoma                              1 (7%)       3 (20%)                   7 (54%)                  
      Mediastinal, Osteosarcoma, Metastatic, Skin      1 (7%)                                                                       
   Lymph Node, Mandibular                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)       1 (7%)       2 (13%)                   3 (20%)                  
   Lymph Node, Mesenteric                             (15)         (15)         (15)         (14)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)       2 (13%)      1 (7%)       5 (33%)                  
   Spleen                                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                              1 (7%)       1 (7%)       3 (20%)      1 (7%)       7 (47%)                  
   Thymus                                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)       2 (13%)      2 (13%)      4 (27%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)                      
      Osteosarcoma                                     1 (7%)                                                                       
      Squamous Cell Papilloma                                       1 (7%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) MALE           0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                                                           (1)                                    
      Hemangiosarcoma                                                                         1 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)       1 (7%)       1 (7%)       4 (27%)                  
   Spinal Cord                                                                               (1)                                    
      Histiocytic Sarcoma                                                                     1 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)                      
      Alveolar/Bronchiolar Adenoma                     1 (7%)                    2 (13%)      5 (33%)      2 (13%)                  
      Alveolar/Bronchiolar Adenoma, Multiple                                                  2 (13%)      1 (7%)                   
      Alveolar/Bronchiolar Carcinoma                   2 (13%)                   1 (7%)       3 (20%)                               
      Alveolar/Bronchiolar Carcinoma, Multiple                      1 (7%)                                                          
      Histiocytic Sarcoma                              1 (7%)       1 (7%)       2 (13%)      2 (13%)      6 (40%)                  
      Osteosarcoma, Metastatic, Skin                   1 (7%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                                 (1)                                                              
      Adenoma                                                       1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)                      
      Histiocytic Sarcoma                                           1 (7%)       2 (13%)      2 (13%)      5 (33%)                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)                      
      Histiocytic Sarcoma                              2 (13%)      6 (40%)      9 (60%)      5 (33%)     11 (73%)                  
      Lymphoma Malignant                               2 (13%)                                1 (7%)                                
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) MALE           0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 SYSTEMIC LESIONS - cont                                                                                                            
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  10                                                               
                                                                                                                                   
NTP Experiment-Test: 99035-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: 26-39 WEEKS                         TRANSGENIC MODEL EVALUATION II (GLYCIDOL)                         Date: 03/31/04  
Route: GAVAGE                                                                                                     Time: 12:54:57  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         P16(INK4A)/(+/-) (C57BL/6) MALE           0 MG/KG      25 MG/KG     50 MG/KG     100          200                          
                                                                                          MG/KG        MG/KG                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             7           8          12          12          12                           
     Total Primary Neoplasms                            8           9          12          17          15                           
                                                                                                                                    
   Total Animals with Benign Neoplasms                  1           2           2           7           4                           
     Total Benign Neoplasms                             1           2           2           7           4                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms               6           7          10           9          11                           
     Total Malignant Neoplasms                          7           7          10          10          11                           
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              1                                                                           
     Total Metastatic Neoplasm                          2                                                                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  11                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------